The latest shared research on Informa Healthcare Communications
GSK: Fluticasone Propionate/Salmeterol Combination in Children with Asthma – Key Cardiac and Overall Safety Results (Advair)
Abstract from: Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results, Jennifer S. Li et al., Clinical Research and Regulatory Affairs Sep 2010, Vol. 27, No. 3, Pages 87-95: 87-95. This study studied the safety of fluticasone propionate/salmeterol combination (FSC) 100/50 HFA (2 inhalations of 50/25 mcg) twice daily, compared with fluticasone propionate (FP) 100 HFA (two inhalations of 50 mcg) twice daily, over a 12-week treatment period in subjects aged 4–11 years with persistent asthma. Of the 350 subjects randomized to receive double-blind treatment, 173 received FSC 100/50 HFA and 177 received FP 100 HFA. The two ...
GSK: Lapatinib for Breast Cancer – A Review of the Current Literature (Tykerb)
Abstract from: Lapatinib for breast cancer: a review of the current literature, Robyn J MacFarlane, Karen A Gelmon, Expert Opinion on Drug Safety Jan 2011, Vol. 10, No. 1, Pages 109-121: 109-121. Importance of the field: The identification of HER-2 expression as a predictive and prognostic marker revolutionized breast cancer. Trastuzumab, a humanized mAb, improves survival in both early and advanced HER-2 overexpressing breast cancer. However, many cancers either do not respond or develop resistance to this agent. Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast ...
New research on Novartis’ Gleevec: Adjuvant imatinib for gastrointestinal stromal tumors – the current situation and problems
Abstract from: Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems, Jian-Hong Zhong et al., Scandinavian Journal of Gastroenterology Jun 2011, Vol. 46, No. 6, Pages 645-651: 645-651. Objective: To review the current situation and find out the current problems of adjuvant imatinib for gastrointestinal stromal tumors (GISTs). Methods: Searching for articles and records about imatinib for GISTs, especially adjuvant imatinib for GISTs, on MEDLINE, EMBASE and international conference on gastrointestinal. Results: GISTs are derived from mesenchymal cells of the gastrointestinal tract. The standard treatment for primary GISTs is to resect the tumor together with the negative margins completely without tumor rupture and ...
Latest Roche Research: Clinical Outcome with Bevacizumab in Patients with Recurrent High-Grade Glioma Treated Outside Clinical Trials
Abstract from: Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials, Silvia Hofer et al., Acta Oncologica Jun 2011, Vol. 50, No. 5, Pages 630-635: 630-635. Background: Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest. Patients and methods: In an ongoing registry data were collected from patients who have received BEV for the treatment of recurrent HGG. The primary objective was the identification of any clinical benefit ...
Latest Roche Research: Maintenance Rituximab Following Induction Chemo-Immunotherapy for Mantle Cell Lymphoma
Abstract from: Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network, Vaishalee P. Kenkre et al., Leukemia & Lymphoma : 1-6. Posted online on 17 May 2011. Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3–5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free ...
AstraZeneca: SATURN trial for Rosuvastatin
Abstract from: Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN), Stephen J. Nicholls et al., Current Medical Research and Opinion Jun 2011, Vol. 27, No. 6, Pages 1119-1129 Background: Previous imaging studies have demonstrated that the beneficial impact of high-dose statins on the progression of coronary atherosclerosis associates with their ability to lower levels of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) and to raise high-density lipoprotein cholesterol (HDL-C). The Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN (SATURN, NCT00620542) aims ...
AstraZeneca: Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
Abstract from: Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus, Jean Doucet, Antonio Chacra, Pierre Maheux, Jane Lu, Susan Harris, Julio Rosenstock, Current Medical Research and Opinion Apr 2011, Vol. 27, No. 4, Pages 863-869. Objective: To assess the safety and efficacy of saxagliptin (5 mg once-daily) in older patients (≥65 years of age) with inadequately controlled type 2 diabetes. Research design and methods: In this retrospective subgroup analysis, data from five randomized, double-blind, placebo-controlled, multicenter, 24-week, phase 3 trials were included. The primary studies evaluated saxagliptin 5 mg once-daily (monotherapy or add-on) in patients aged 18–77 years with HbA1c ≥7.0% ...
The Cardiovascular Risk of Tiotropium: Is It Real?
Note: PharmaShare members get exclusive access to the full text of this article. Sign-in or register to access the link. Abstract from: Mario Cazzola, Luigino Calzetta, Maria Gabriella Matera Expert Opinion on Drug Safety Sep 2010, Vol. 9, No. 5, Pages 783-792: 783-792. Importance of the field: Anticholinergic agents are of noteworthy value in the treatment of chronic obstructive pulmonary disease (COPD), but concerns have been raised about a possible association between their use and cardiovascular (CV) morbidity and mortality. In this review, we have examined whether and why an anticholinergic agent, and in particular tiotropium, might cause ...
A Look at BIBF 1120 for the Treatment of Non-Small Cell Lung Cancer
Note: PharmaShare members get exclusive access to the full text of this article. Sign-in or register to access the link. Abstract from: Martin Reck, Expert Opinion on Investigational Drugs Jun 2010, Vol. 19, No. 6, Pages 789-794: 789-794. Importance of the field: For patients with advanced non-small cell lung cancer (NSCLC), chemotherapy offers modest benefits and outcomes are poor. Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a fundamental process for tumor growth and development. Tumor vasculature is therefore emerging as an important target for cancer therapy. Areas covered in this review: This expert ...
